Experts highlighted recent gene therapy approvals for inherited immune disorders while addressing ongoing challenges in manufacturing, long-term safety, and patient access.
|Articles|September 30, 2017
- September 2017 Immunization
- Volume 83
- Issue 9
Can You Read These Rxs? (September 2017)
Can you figure out what these prescriptions say?
Advertisement
Send in your eye-straining, baffling prescriptions—now via e-mail and fax as well as regular mail! Submissions must include a clean photocopy or scanned image of the Rx; your institution’s name and location; your name and title; the correct name of the drug(s), strength, and dosing requirements; and your phone number. You can e-mail scanned Rxs to rmarotta@pharmacytimes.com; fax them to 609-257-0701; or mail them to Can You Read These Rxs?, Pharmacy Times, 2 Clarke Drive, Suite 100, Cranbury, NJ 08512.
Articles in this issue
almost 9 years ago
Ensuring Patient Access to Asthma Therapy: Perspectives for Pharmacistsabout 9 years ago
Case Studies (September 2017)about 9 years ago
Pet Peeves (September 2017)about 9 years ago
Our Unsung Defenders Against Diseaseabout 9 years ago
Tamoxifen: New Developmentsabout 9 years ago
Qternabout 9 years ago
House Bill Takes Aim at Direct-to-Consumer AdvertisingAdvertisement
Related to this article
Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
At the 2026 ASTCT Gene Therapy Summit, experts highlighted how chronic pain, psychological challenges, and neurologic complications may persist despite successful treatment.
RSV hospitalization raised short-term invasive pneumococcal disease risk, especially among unvaccinated individuals.
ADA guidance ties monitoring choices to therapy, risk, and preference. Brooke Hudspeth, PharmD, explains how pharmacists help individualize the plan.
Twice-daily metronidazole dosing had outcomes comparable with those of thrice-daily dosing for confirmed anaerobic infections, minimizing drug exposure and cost while maintaining clinical efficacy.
Pharmacists navigate BCMA therapy sequencing in relapsed/refractory multiple myeloma, weighing linvoseltamab logistics, community readiness, safety monitoring, and smoother care transitions.
The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.
Advertisement
Advertisement
Trending on Pharmacy Times
1
CVS Health to Split Into 2 Public Companies, Separating Retail and Specialty Pharmacy
2
Community Pharmacists Guide Patients New to Glucose Monitoring
3
FDA Approves Tildrakizumab for Adults With Psoriatic Arthritis
4
Is Less More? Comparing Metronidazole Dosing in Confirmed Anaerobic Infections
5